BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role

BIOCRYST PHARMACEUTICALS INC

CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.
CEO Jon P. Stonehouse appointed Interim CFO and Interim Principal Accounting Officer effective April 9.
Company hired former public biotech CFO as financial consultant to support Stonehouse during CFO search.
No change to Stonehouse's compensation arrangements resulting from the interim appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anthony Doyle

Chief Financial Officer and Interim Principal Accounting Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2025-04-09
Successor: Jon P. Stonehouse
Filed: April 10, 2025, 7:59 PM ET

Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025

Appointed (interim)

Jon P. Stonehouse

Interim Chief Financial Officer and Interim Principal Accounting Officer

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2025-04-09
Filed: April 10, 2025, 7:59 PM ET

appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.

Action: resigned
Role: Chief Financial Officer and Interim Principal Accounting Officer

Exact text from the filing

Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jon P. Stonehouse was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.

Action: appointed
Role: Interim Chief Financial Officer and Interim Principal Accounting Officer

Exact text from the filing

appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-25-002147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.